In 2017, China's foreign trade performance of APIs hit a record high

Pharmaceutical Network March 6 In 2017, with the global economy rebounding obviously and our country's economic development is better than expected, the import and export trade of China's API drugs will reproduce the rapid growth after two years' A new high of 37.84 billion U.S. dollars, an increase of 13.84% over the same period of last year, accounting for 54.5% of the total trade in western medicine and a 16% decrease over 2010. Relatively speaking, the import and export of western medicine and biochemical products with higher added value are in the western medicine trade Its proportion has been increasing, which shows that remarkable achievements have been made in the transformation and upgrading of China's pharmaceutical industry.

In 2017, the export volume of APIs in our country showed a trend of volume and price increase: the export volume reached 8,961,500 MT, a record high, up 8.33% over the same period of last year; the average export price hit a bottoming rebound, up 4.96% YoY, which was slightly higher than the previous year's prices. Under the superposition of the two, the export volume increased by 13.71% over the same period of last year to reach 29.117 billion U.S. dollars.

In the overall favorable environment, most of the raw material drug sub-categories of exports have achieved varying degrees of growth. Bulk raw materials such as vitamins, amino acids, aminoglycosides, anti-pyretic class export growth year on year Reaching double digits. Vitamins outstanding performance, exports increased 46%, exports and the average price increased 14% and 28% respectively, of which exports of VA, VB1, VC, VD and other varieties are up more than 40%. The export of amino acids such as threonine, methionine and glutamic acid increased by more than 40% over the same period of last year, while the export of streptomycin in aminoglycosides reached 83% year-on-year growth while that of gentamicin A year-on-year decrease of 3%. The main export varieties of antipyretic and analgesic drugs such as acetaminophen, ibuprofen and metamizole also all had an increase of 5% -14% over the same period of the previous year. Penicillins, hormones, cephalosporins Su class, tetracycline and other bulk materials drug The export of similar products showed a small increase compared with the same period of previous year, maintaining a steady growth trend. Some categories such as macrolides, sulfonamides and chloramphenicol groups were affected by the decrease in export volume and the export volume decreased to a certain extent.

China's export market of APIs remained basically stable, with Asia, Europe and North America still the top three export markets, accounting for 46%, 27.9% and 14.5% of the total respectively. China's export of raw materials to Asia reached 4.6822 million tons, The value of 13.384 billion US dollars, an increase of 11.59%, the average export price lower than the average price of 12% of the total market exports, indicating that China's export of API drugs to the Asian market, mainly low-cost products, the price is one of the competitive advantage of the European exports of bulk drugs 1,868,900 tons, the value of 81.27 billion US dollars, an increase of 10.59%, the average export price higher than the average export price of 34% of all markets, including EU countries and regions, the average export price of raw materials is even higher than the average price of all markets 49 %; Exports to North America 836,200 tons of raw materials, the value of 4.22 billion US dollars, an increase of 23.91%, the average export price higher than the average price of 55% of the market for all exports to Europe and North America, Indicating that the local market is more concerned about the high quality, high value-added APIs.

In 2017, China's APIs were exported to 195 countries and regions. Against the background of frequent trade disputes with China's APIs and on-site inspections of China's API companies, India is the largest exporter of APIs in China , The import value of China's bulk pharmaceutical products reached 4.447 billion U.S. dollars, up 13.52% year-on-year, showing the trend of both the volume and the price going up. The United States maintained its second seat and imported 3.92 billion U.S. dollars of APIs throughout the year, an increase of 23.84% Is the highest growth rate in the top ten, which is related to the United States lifting the ban on the import of some raw materials and pharmaceutical enterprises in China in 2017. Japan, South Korea, Germany and the Netherlands, respectively, rely on China's exports of its APIs by 10% to 15% Year-on-year growth rate ranked third to sixth place, Italy, Spain also continue to rank among the top 10. In 2017, China's exports of Brazilian raw material rose 23.11%, helping it leapt to China's exports of bulk drugs Destination 7. The top ten occupy 61% of China's exports of bulk drugs, higher export concentration.

In 2017, a total of 11,000 enterprises engaged in the export business of APIs in China, an increase of 707 over the same period of last year. The number of business operators has been increasing for 4 consecutive years, mainly due to the growth of private-owned enterprises. , Which has maintained a strong export vitality. Total export volume in 2017 was 18.036 billion U.S. dollars, up 17.72% over the same period of previous year, accounting for 62% of the total. The number of entrepreneurs increased by 698 units. In recent years, the export volume of bulk pharmaceuticals of state-owned enterprises continued to decrease, In 2017, there was an increase of exports, with an export volume of 3.766 billion U.S. dollars, an increase of 7.57% over the same period of previous year, accounting for 13% of the total. The performance of foreign-funded enterprises also increased, with exports up 7.8% YoY and 25% of the total exports.

Shijiazhuang Pharmaceutical Group, Pharma Pharma, Huahai Pharmaceutical, a Connaught medicine , Federal Pharmaceutical, Zhejiang Medicine, Yi Fan Pharmaceutical, Jiangxi Tianxin, Zhejiang Chemical, Xinhua Pharmaceutical 10 raw materials leading enterprise Ranking the top ten in the list of exporters of APIs in China with a total export value of 2.402 billion U.S. dollars, accounting for 8.25%; 32 enterprises with export value of over 100 million U.S. dollars, and 107 enterprises exceeding 50 million U.S. dollars, accounting for Respectively 18.89% and 36.68%. However, compared to China's 11,000 bulk pharmaceutical exporters, the concentration of export companies is still relatively low.

In 2017, China imported 1.6976 million tons of APIs, an increase of 11.43% over the same period of last year with an import volume of 8.723 billion U.S. dollars, up 14.3% over the same period of last year and a slight increase of 2.57% over the same period of last year. The growth in the pharmaceutical market demand; Second, under the pressure of domestic environmental protection, some enterprises have switched from using self-produced bulk drugs to international purchase.

Imports of bulk APIs, such as vitamins, cephalosporins and cardiovascular system, accelerated, with the volume of imports increasing over 30%, leading to an increase of 12%, 15% and 362% respectively in import value, the latter increase The larger figures were due to the significant increase in the import of atorvastatin calcium and acarbose; macrolides, sulfonamides, penicillins, narcotic drugs and other previously imported small amounts of APIs showed a large import amount The rate of increase was in the range of 32% to 225%. There were also some raw materials such as amino acids, hormones, tetracyclines, antipyretic analgesia, etc. The import amount decreased by 10% to 30%.

In 2017, China imported APIs mainly from Europe, Asia and Europe with imports of US $ 4446 million and US $ 31140000000, up by 10.22% and 16.13% respectively over the same period of last year, accounting for 87% of the total imports of APIs in China. In terms of specific countries and regions, Ireland, with its export volume of 1.064 billion U.S. dollars and its year-on-year increase of 36.5%, has become China's largest importer of bulk drug products. Its growth mainly depends on cardiovascular and anti-infective APIs. Japan and the United States also exported more than 1 billion U.S. dollars of raw materials to China, ranking second and third in the list of China's raw material import sources.

In 2017, the number of importers engaged in the import of APIs in China increased by 172 to 6469 as compared with 2016. Among them, the number of private enterprises surpassed that of foreign-funded enterprises for the first time to 3,076, but their import performance still only accounted for the import of raw material medicine in China 21% of the total, outstanding performance of Keyuan Xinhai, Yangtze River and other enterprises import performance; 3037 foreign-funded enterprises operating in China imported 72% of the total amount of raw materials, an increase of 14.5%, Pfizer, General Electric, Squibb, AstraZeneca, Roche , Bayer, Degussa, Merck, Eisai, Shi Weiya and other multinational corporations in China's import business of bulk drugs continue to be in a leading position.